Addex Therapeutics Reports Promising Preclinical Results for Chronic Cough Treatment

The latest update is out from Addex Therapeutics ( (CH:ADXN) ).

Addex Therapeutics announced promising preclinical results for its GABAB positive allosteric modulator (PAM) in treating chronic cough, demonstrating superior efficacy and tolerability compared to existing treatments like nalbuphine and codeine. The company plans to advance this candidate into IND enabling studies, highlighting its potential as a once-daily treatment for refractory chronic cough, thereby strengthening Addex’s position in the biopharmaceutical industry and potentially offering better treatment options for patients.

More about Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in developing novel small molecule allosteric modulators for neurological disorders. The company’s lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, while its partner, Indivior, is developing a GABAB PAM drug candidate for substance use disorders. Addex is also advancing its own GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which focuses on allosteric modulator programs for various neurological conditions. Addex is listed on the SIX Swiss Exchange and NASDAQ.

Average Trading Volume: 127,424

Current Market Cap: CHF10.84M

For detailed information about ADXN stock, go to TipRanks’ Stock Analysis page.